Vanguard Group’s Zivo Bioscience, Inc. Common Stock ZIVO Stock Holding History

Vanguard Group’s Portfolio ZIVO Stock Details ZIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,811	Closed	-$170K	–	4551
2023 Q3	$170K	Buy	21,811 +2,423	+12%	+$27K	﹤0.01%	4281
2023 Q2	$282K	Buy	19,388 +1,165	+6%	+$19.8K	﹤0.01%	4252
2023 Q1	$337K	Buy	18,223 +1,589	+10%	+$29.5K	﹤0.01%	4221
2022 Q4	$250K	Buy	16,634 +187	+1%	+$3.26K	﹤0.01%	4264
2022 Q3	$276K	Buy	16,447 +368	+2%	+$8.11K	﹤0.01%	4363
2022 Q2	$378K	Buy	16,079 +668	+4%	+$13.4K	﹤0.01%	4356
2022 Q1	$359K	Buy	15,411 +2,524	+20%	+$50.3K	﹤0.01%	4445
2021 Q4	$221K	Buy	+12,887	New	+$270K	﹤0.01%	4550

Other funds holding ZIVO

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return

Vanguard Group's ZIVO Position: Q4 2023 in Review

Vanguard Group sold out of Zivo Bioscience, Inc. Common Stock (ZIVO) in Q4 2023, closing a stake of 21,811 shares — an estimated $170K sold.

Vanguard Group first reported a position in ZIVO in Q4 2021 and held it in 8 quarters. The position peaked at $378K in Q2 2022. 2 funds tracked by Wall St. Rank hold ZIVO as of Q4 2023.

Vanguard Group reported no remaining Zivo Bioscience, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Vanguard Group sold 21,811 Zivo Bioscience, Inc. Common Stock shares in Q4 2023, an estimated $170K.
Vanguard Group first reported a position in Zivo Bioscience, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Vanguard Group's Zivo Bioscience, Inc. Common Stock position peaked at $378K in Q2 2022.
2 funds tracked by Wall St. Rank held Zivo Bioscience, Inc. Common Stock as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.